Reginald B H Tan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8613596/publications.pdf Version: 2024-02-01



RECINALD R H TAN

#	Article	IF	CITATIONS
1	Trimorphs of a pharmaceutical cocrystal involving two active pharmaceutical ingredients: potential relevance to combination drugs. CrystEngComm, 2009, 11, 1823-1827.	2.6	134
2	Environmental impacts of conventional plastic and bio-based carrier bags. International Journal of Life Cycle Assessment, 2010, 15, 284-293.	4.7	99
3	Direct Growth of Î ³ -Glycine from Neutral Aqueous Solutions by Slow, Evaporation-Driven Crystallization. Crystal Growth and Design, 2006, 6, 1746-1749.	3.0	90
4	Modeling and Computational Fluid Dynamicsâ `Population Balance Equationâ `Micromixing Simulation of Impinging Jet Crystallizers. Crystal Growth and Design, 2009, 9, 156-164.	3.0	82
5	Co-Crystals and Co-Crystal Hydrates of the Antibiotic Nitrofurantoin: Structural Studies and Physicochemical Properties. Crystal Growth and Design, 2012, 12, 5925-5938.	3.0	72
6	Influence of Solution Speciation of Impurities on Polymorphic Nucleation in Glycine. Crystal Growth and Design, 2008, 8, 179-185.	3.0	66
7	Stable polymorphs: difficult to make and difficult to predict. CrystEngComm, 2007, 9, 128.	2.6	62
8	Mechanical properties and antibiotic release characteristics of poly(methyl methacrylate)-based bone cement formulated with mesoporous silica nanoparticles. Journal of the Mechanical Behavior of Biomedical Materials, 2017, 72, 163-170.	3.1	60
9	Environmental impacts of conventional plastic and bio-based carrier bags. International Journal of Life Cycle Assessment, 2010, 15, 338-345.	4.7	59
10	Robust Bayesian estimation of kinetics for the polymorphic transformation of <scp>L</scp> â€glutamic acid crystals. AICHE Journal, 2008, 54, 3248-3259.	3.6	54
11	Impact Assessment of Waste Management Options in Singapore. Journal of the Air and Waste Management Association, 2006, 56, 244-254.	1.9	51
12	Determination of Critical Supersaturation from Microdroplet Evaporation Experiments. Crystal Growth and Design, 2006, 6, 1175-1180.	3.0	49
13	Solidâ€Based Hydrothermal Synthesis and Characterization of Alumina Nanofibers with Controllable Aspect Ratios. Journal of the American Ceramic Society, 2009, 92, 1311-1316.	3.8	46
14	Effect of API-Polymer Miscibility and Interaction on the Stabilization of Amorphous Solid Dispersion: A Molecular Simulation Study. Industrial & Engineering Chemistry Research, 2017, 56, 12698-12707.	3.7	45
15	Novel Formulation of Large Hollow Nanoparticles Aggregates as Potential Carriers in Inhaled Delivery of Nanoparticulate Drugs. Industrial & Engineering Chemistry Research, 2006, 45, 3697-3706.	3.7	43
16	Precise tailoring of the crystal size distribution by controlled growth and continuous seeding from impinging jet crystallizers. CrystEngComm, 2011, 13, 2006.	2.6	43
17	Nucleation and growth kinetics estimation for l-phenylalanine hydrate and anhydrate crystallization. CrystEngComm, 2011, 13, 1197.	2.6	40
18	Quality by Design (QbD)-Based Crystallization Process Development for the Polymorphic Drug Tolbutamide. Crystal Growth and Design, 2011, 11, 3027-3038.	3.0	40

REGINALD B H TAN

#	Article	IF	CITATIONS
19	Template-induced polymorphic selectivity: the effects of surface chemistry and solute concentration on carbamazepine crystallisation. CrystEngComm, 2014, 16, 4927-4930.	2.6	40
20	Selective Crystallization of the Metastable Anhydrate Form in the Enantiotropic Pseudo-Dimorph System of <scp>l</scp> -Phenylalanine using Concentration Feedback Control. Crystal Growth and Design, 2009, 9, 3052-3061.	3.0	38
21	Anisotropic Crystal Growth Inhibition by Polymeric Additives: Impact on Modulation of Naproxen Crystal Shape and Size. Crystal Growth and Design, 2017, 17, 4844-4854.	3.0	37
22	Template-induced nucleation for controlling crystal polymorphism: from molecular mechanisms to applications in pharmaceutical processing. CrystEngComm, 2019, 21, 4122-4135.	2.6	37
23	Crystal Engineering of Tegafur Cocrystals: Structural Analysis and Physicochemical Properties. Crystal Growth and Design, 2014, 14, 6557-6569.	3.0	35
24	Establishing template-induced polymorphic domains for API crystallisation: the case of carbamazepine. CrystEngComm, 2015, 17, 6384-6392.	2.6	33
25	Crystallizing Micronized Particles of a Poorly Water-Soluble Active Pharmaceutical Ingredient: Nucleation Enhancement by Polymeric Additives. Crystal Growth and Design, 2016, 16, 749-758.	3.0	32
26	Synergistic combination dry powders for inhaled antimicrobial therapy: Formulation, characterization and in vitro evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 275-284.	4.3	31
27	Nucleation of Elusive Crystal Polymorphs at the Solution–Substrate Contact Line. Crystal Growth and Design, 2013, 13, 1180-1186.	3.0	30
28	Implementation of Focused Beam Reflectance Measurement (FBRM) in Antisolvent Crystallization to Achieve Consistent Product Quality. Crystal Growth and Design, 2010, 10, 3668-3674.	3.0	27
29	Conformational Polymorphs of a Muscle Relaxant, Metaxalone. Crystal Growth and Design, 2011, 11, 4101-4109.	3.0	24
30	Clay as a matrix former for spray drying of drug nanosuspensions. International Journal of Pharmaceutics, 2014, 465, 83-89.	5.2	23
31	Operating Strategy to Produce Consistent CSD in Combined Antisolvent-Cooling Crystallization Using FBRM. Industrial & Engineering Chemistry Research, 2012, 51, 13773-13783.	3.7	22
32	Application of transglycosylated stevia and hesperidin as drug carriers to enhance biopharmaceutical properties of poorly-soluble artemisinin. Colloids and Surfaces B: Biointerfaces, 2018, 161, 83-93.	5.0	20
33	Precise Habit Modification of Polar <scp>dl</scp> -Alanine Crystal by Control of Supersaturation. Crystal Growth and Design, 2011, 11, 3941-3946.	3.0	18
34	The Effect and Counter-Effect of Impurities on Crystallization of an Agrochemical Active Ingredient: Stereochemical Rationalization and Nanoscale Crystal Growth Visualization. Crystal Growth and Design, 2011, 11, 492-500.	3.0	18
35	A novel inhaled multi-pronged attack against respiratory bacteria. European Journal of Pharmaceutical Sciences, 2015, 70, 37-44.	4.0	17
36	Effects of Common Inorganic Salts on Glycine Polymorphic Transformation: An Insight into Salt-Dependent Polymorphic Selectivity. Crystal Growth and Design, 2016, 16, 6499-6505.	3.0	17

REGINALD B H TAN

#	Article	IF	CITATIONS
37	Dissolution and physicochemical stability enhancement of artemisinin and mefloquine co-formulation via nano-confinement with mesoporous SBA-15. Colloids and Surfaces B: Biointerfaces, 2017, 155, 560-568.	5.0	16
38	Tailored Antibiotic Combination Powders for Inhaled Rotational Antibiotic Therapy. Journal of Pharmaceutical Sciences, 2016, 105, 1501-1512.	3.3	15
39	Design Space for Polymorphic Co-crystallization: Incorporating Process Model Uncertainty and Operational Variability. Crystal Growth and Design, 2014, 14, 3949-3957.	3.0	14
40	Particle Size Control in Batch Crystallization of Pyrazinamide on Different Scales. Organic Process Research and Development, 2016, 20, 2100-2107.	2.7	12
41	Online Classification of Mixed Co-Crystal and Solute Suspensions using Raman Spectroscopy. Organic Process Research and Development, 2016, 20, 1068-1074.	2.7	12
42	Understanding the Salt-Dependent Outcome of Glycine Polymorphic Nucleation. Pharmaceutics, 2021, 13, 262.	4.5	12
43	A model for bubble-bubble and bubble-wall interaction in bubble formation. AICHE Journal, 2006, 52, 86-98.	3.6	8
44	Experimental Studies of Hydrodynamics and Regime Transition in Bubble Columns. Canadian Journal of Chemical Engineering, 2006, 84, 63-72.	1.7	8
45	Characterisation framework development for the SIMPASS (Singapore IMPact ASSessment) methodology. International Journal of Life Cycle Assessment, 2012, 17, 89-95.	4.7	6
46	Probing the Mechanisms Underlying Electrolyte-Assisted Nucleation Enhancement of <scp>dl</scp> -Alanine. Crystal Growth and Design, 2014, 14, 1406-1411.	3.0	6
47	Interfacial Element Modeling of Bubble Formation with Liquid Viscosity. Journal of Chemical Engineering of Japan, 2005, 38, 478-485.	0.6	5
48	Investigation of Drying Geldart D and B Particles in Different Fluidization Regimes. Canadian Journal of Chemical Engineering, 2008, 84, 656-662.	1.7	4
49	Inhaled mucoactive particles with tailored architecture for enhanced aerodynamicity, stability and efficacy. International Journal of Pharmaceutics, 2019, 572, 118740.	5.2	3
50	The New International Standards for Life Cycle Assessment: ISO 14040 and ISO 14044. Journal of Life Cycle Assessment Japan, 2007, 3, 58-64.	0.0	2
51	Relating Alkyl Chain Length of Additives to Wax Crystallization Inhibition: Toward the Rational Design of Pour Point Depressants. Crystal Growth and Design, 2022, 22, 4031-4042.	3.0	2
52	Theoretical Modeling of Bubbling Regimes in Bubble Formation with Bubble-Bubble and Bubble-Wall Interactions. Journal of Chemical Engineering of Japan, 2008, 41, 453-459.	0.6	1
53	Synergistic combination dry powders for inhaled antimicrobial therapy. , 2013, , .		1
54	A Non-Spherical Model for Bubble Formation with Chemical Reaction at a Submerged Orifice. Journal of Chemical Engineering of Japan, 2008, 41, 953-960.	0.6	0

#	Article	IF	CITATIONS
55	Visualizing powder de-agglomeration upon impact with simultaneous flowing charge behaviour. , 2013, , .		0
56	Reply to the â€~Comment on "Trimorphs of a pharmaceutical cocrystal involving two active pharmaceutical ingredients: potential relevance to combination drugs―by S. Aitipamula, P. S. Chow and R. B. H. Tan, <i>CrystEngComm</i> , 2009, 11 , 1823'. CrystEngComm, 2018, 20, 373-374.	2.6	0
57	Life Cycle Assessment Methodology: Ongoing Developments and Outlook. , 2022, , 1-21.		0